AIEOP-BFM ALL 2017 is the EHA 2026 Plenary Abstract Session study S103 testing replacement of…
Browsing: biotech analysis
RISE UP is the EHA 2026 Plenary Abstract Session study S102 evaluating mitapivat in sickle…
frontMIND is the EHA 2026 Plenary Abstract Session study S101 evaluating tafasitamab plus lenalidomide and…
MonumenTAL-3 is the Plenary Abstract Session study S100 evaluating talquetamab plus daratumumab with or without…
LB5006 / EHA-7249 is the EHA 2026 first-in-human study of LB2501, an in vivo CD19/CD20…
LB5007 / EHA-7241 is the RevSTAR-123 (AVC-201-01) study of switchable allogeneic CD123-directed CAR-T therapy in…
LB5003 / EHA-7251 is an EHA 2026 late-breaking study of BCMA CAR-T therapy in refractory…
SENTRY is an EHA 2026 late-breaking Phase 3 myelofibrosis study of selinexor plus ruxolitinib in…
ImmunoPRISM is an EHA 2026 LB5008 Phase 2 study of teclistamab versus lenalidomide-dexamethasone in high-risk…
HOVON156/AMLSG28-18/PASHA is EHA 2026 LB5005, a Phase 3 head-to-head study of gilteritinib versus midostaurin in…